iCAD (NASDAQ:ICAD – Get Free Report) issued its quarterly earnings data on Wednesday. The technology company reported ($0.03) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.02, Zacks reports. The firm had revenue of $5.41 million for the quarter, compared to analyst estimates of $4.72 million. iCAD had a negative return on equity of 15.65% and a negative net margin of 17.81%.
iCAD Price Performance
Shares of NASDAQ ICAD opened at $2.09 on Friday. iCAD has a 1 year low of $1.18 and a 1 year high of $3.78. The stock has a market capitalization of $55.47 million, a P/E ratio of -16.08 and a beta of 1.95. The company’s 50-day moving average is $2.65 and its 200 day moving average is $2.05.
Wall Street Analyst Weigh In
Separately, StockNews.com cut shares of iCAD from a “hold” rating to a “sell” rating in a report on Tuesday.
About iCAD
iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.
Recommended Stories
- Five stocks we like better than iCAD
- Dividend Payout Ratio Calculator
- Word-of-Mouth Winners: 2 Stocks Growing Without Big Ad Budgets
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Cybersecurity Stocks Surge as $32B Deal Reshapes the Industry
- The Role Economic Reports Play in a Successful Investment Strategy
- Could Palantir’s R1 Deal Be the Catalyst for a Stock Surge?
Receive News & Ratings for iCAD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iCAD and related companies with MarketBeat.com's FREE daily email newsletter.
